Moderna, Inc. Hits New 52-Week Low at USD 23.04 Amid Declining Sales

Moderna, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 23.04 on November 7, 2025. This significant decline reflects a challenging year for the company, with its stock price plummeting by 83.48% over the past year, starkly contrasting with the S&P 500's performance of 12.65% during the same period.
The company's financial metrics reveal a loss-making position, with a negative return on equity of -30.89% and a debt-to-equity ratio of -0.54. Additionally, Moderna has not offered any dividends, maintaining a dividend yield of 0.00%. The price-to-book ratio stands at 1.03, indicating a valuation that may not attract investors under current conditions.

Recent financial results have shown a steep decline in net sales, which fell by 82.12% to USD 142 million, while net profit for the first nine months reported a loss of USD 2,916 million, growing at -30.35%. The rising raw material costs, which increased by 172.78% year-over-year, further complicate the company's financial landscape. Overall, Moderna's performance has consistently underperformed against market benchmarks, raising concerns about its future trajectory.